The Journal of Cosmetic Dermatology published its review of polydeoxyribonucleotide, or PDRN, in the November 2026 issue, under the headline "Are PDRNs the Next Magic Ingredient? From Cosmetic Hype to Regenerative Bioengineering." The piece is a synthesis of existing literature, not a new clinical trial. Separating what that literature documents from what clinic marketing now claims about PDRN shows two different timelines for the same molecule.
PDRN's clinical record starts decades before any viral facial. Mastelli S.r.l., a company based in Sanremo, Italy, has operated for roughly 70 years. Its product Placentex, a topical and injectable wound-healing agent derived from trout and fish DNA, has been used in Italy for connective-tissue repair since long before PDRN reached cosmetic clinics, according to an interview with Mastelli's leadership and company background from Farmacia Igea.
The ingredient's path to aesthetic clinics ran through South Korea. Rejuran, made by PharmaResearch, launched in South Korea and holds approval from the country's Ministry of Food and Drug Safety. Rejuran is the brand most responsible for popularizing PDRN skin boosters in Asian aesthetic clinics before the treatment spread on social media in the West, per The Zoe Report. In March 2026, Rejuran Cosmetics opened a shelf at Sephora stores in the United States, shipping a topical serum line built around the same ingredient, according to a Barchart press release.
No FDA approval exists for injectable PDRN for aesthetic use in the United States. Clinics that offer it do so off label, and some sources describe it as unavailable as a legal injectable product in the country at all, per an IMCAS review and Cosmetics & Toiletries. South Korea regulates PDRN as a pharmaceutical and treats higher-molecular-weight polynucleotide injectables as a separate medical-device category. The United States has no approved drug label for either category, so the two-tier Korean system has no American counterpart.
The strongest evidence for PDRN sits away from the cosmetic claims. A 2026 systematic review in Cureus pooled seven randomized controlled trials covering 183 participants and found the clearest benefit in wound healing: diabetic ulcers, skin graft donor sites, re-epithelialization. Studies testing PDRN for cosmetic rejuvenation were fewer, smaller, and less rigorously designed, according to the Cureus review.
The literature behind PDRN also has a funding thread worth naming. A corrigendum in Frontiers in Pharmacology discloses that an author of a PDRN review received research support from Mastelli, the same manufacturer whose Placentex product anchors much of the foundational PDRN data, per the Frontiers disclosure.
The hype side of the JCD headline has its own paper trail. Viral coverage branded the treatment the "salmon sperm facial," and both Kim Kardashian and Jennifer Aniston have publicly said they tried it. Kardashian's post drove a surge in clinic bookings, reported by AOL. Aniston gave a different account: she said she wasn't sure if it did anything. Some med spas price the treatment starting around $1,000 a session.
Medical-grade PDRN is purified fragmented DNA, extracted and processed from fish cells. It isn't raw fish tissue applied to skin, whatever the marketing shorthand suggests. With a fish-protein allergy, skip it, since hypersensitivity to fish protein is a cited contraindication in the clinical literature. Brands have begun developing plant-based and lab-synthesized alternatives in response to that allergy risk and to sourcing questions about the fish-derived original. Aniston's shrug, sitting next to Kardashian's bookings surge and a $1,000 price tag, is the gap this story keeps circling: a wound-care molecule with seven small trials behind it, now sold at retail under a name built for social media.
